Palisade Bio Inc PALI Enters Exclusive Worldwide Licensing Agreement with Giiant Pharma for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it has entered into a licensing agreement with Giiant Pharma, Inc. (“Giiant”). The license provides the Company with the exclusive worldwide rights to develop, manufacture and…Read More